Clinical Trial Update: 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER) [Phase 2]

View source ↗

Summary

A Phase 2 trial update investigating 12 weeks of docetaxel plus trastuzumab in small, node-negative, HER2-positive breast cancer (SOBER). Status is unknown base…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN